Center for Stem Cell Therapeutics and Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Neuro Oncol. 2018 Jan 22;20(2):215-224. doi: 10.1093/neuonc/nox138.
MicroRNAs (miRs) are known to play a pivotal role in tumorigenesis, controlling cell proliferation and apoptosis. In this study, we investigated the potential of miR-7 to prime resistant tumor cells to apoptosis in glioblastoma (GBM).
We created constitutive and regulatable miR-7 expression vectors and utilized pharmacological inhibition of caspases and genetic loss of function to study the effect of forced expression of miR-7 on death receptor (DR) pathways in a cohort of GBM with established resistance to tumor necrosis factor apoptosis inducing ligand (TRAIL) and in patient-derived primary GBM stem cell (GSC) lines. We engineered adeno-associated virus (AAV)-miR-7 and stem cell (SC) releasing secretable (S)-TRAIL and utilized real time in vivo imaging and neuropathology to understand the effect of the combined treatment of AAV-miR-7 and SC-S-TRAIL in vitro and in mouse models of GBM from TRAIL-resistant GSC.
We show that expression of miR-7 in GBM cells results in downregulation of epidermal growth factor receptor and phosphorylated Akt and activation of nuclear factor-kappaB signaling. This leads to an upregulation of DR5, ultimately priming resistant GBM cells to DR-ligand, TRAIL-induced apoptotic cell death. In vivo, a single administration of AAV-miR-7 significantly decreases tumor volumes, upregulates DR5, and enables SC-delivered S-TRAIL to eradicate GBM xenografts generated from patient-derived TRAIL-resistant GSC, significantly improving survival of mice.
This study identifies the unique role of miR-7 in linking cell proliferation to death pathways that can be targeted simultaneously to effectively eliminate GBM, thus presenting a promising strategy for treating GBM.
已知 microRNAs (miRs) 在肿瘤发生中发挥关键作用,控制细胞增殖和凋亡。在这项研究中,我们研究了 miR-7 使胶质母细胞瘤 (GBM) 中的耐药肿瘤细胞对细胞凋亡敏感的潜力。
我们构建了组成型和可调节的 miR-7 表达载体,并利用半胱天冬酶的药理学抑制和基因功能丧失来研究强制表达 miR-7 对一组对肿瘤坏死因子凋亡诱导配体 (TRAIL) 耐药的 GBM 中死亡受体 (DR) 途径的影响,以及在患者来源的原发性 GBM 干细胞 (GSC) 系中。我们设计了腺相关病毒 (AAV)-miR-7 和干细胞 (SC) 释放可分泌 (S)-TRAIL,并利用实时体内成像和神经病理学来了解 AAV-miR-7 和 SC-S-TRAIL 联合治疗在体外和 TRAIL 耐药 GSC 的 GBM 小鼠模型中的效果。
我们表明,GBM 细胞中 miR-7 的表达导致表皮生长因子受体和磷酸化 Akt 的下调以及核因子-κB 信号的激活。这导致 DR5 的上调,最终使耐药 GBM 细胞对 DR 配体 TRAIL 诱导的凋亡细胞死亡敏感。在体内,单次给予 AAV-miR-7 可显著降低肿瘤体积,上调 DR5,并使 SC 递送的 S-TRAIL 能够根除源自患者来源的 TRAIL 耐药 GSC 的 GBM 异种移植物,显著提高小鼠的存活率。
这项研究确定了 miR-7 在将细胞增殖与死亡途径联系起来的独特作用,可同时靶向这些途径以有效消除 GBM,从而为治疗 GBM 提供了一种有前途的策略。